NYSE
$17.82▲ 3.97%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $61.9MShares out 3.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 10.6After-hours26.10.07 06:544Ownership#●●●
Pelthos Therapeutics Inc.
Insider Peter Greenleaf of Pelthos Therapeutics Inc. filed a Form 4 on October 6, 2026, regarding a change in beneficial ownership of securities effective October 2, 2026. This filing serves as the official record of the insider's equity transaction.…more
$17.82+3.97%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 06:534Ownership
Pelthos Therapeutics Inc.
Insider Ezra M. Friedberg of Pelthos Therapeutics Inc. reported a change in beneficial ownership of securities effective October 2, 2026. This filing is a standard Form 4 disclosure regarding insider holdings.…more
$17.82+3.97%vs prev closeView filingShare - 10.6After-hours26.10.07 06:534Ownership
Pelthos Therapeutics Inc.
Insider Matthew Pauls of Pelthos Therapeutics Inc. reported a change in beneficial ownership of securities effective October 2, 2026. This filing is a standard Form 4 disclosure regarding insider holdings.…more
$17.82+3.97%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Pre-market26.10.06 21:12#●●●#●●●
Pelthos Therapeutics Signs Agreement to Expand Access to ZELSUVMI
Pelthos Therapeutics has entered into an agreement to increase access to its product, ZELSUVMI. However, specific financial terms or details regarding the impact of this agreement were not disclosed.…more
$17.82+3.97%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.13Pre-market26.08.13 20:10
●●●●●●●● ●●●●● ●●●●●●
Pelthos Therapeutics reported a 45% quarter-over-quarter revenue increase to $15.4 million, driven by strong adoption of its lead product, Zelsuvmi. While commercial performance is improving, the company continues to post net losses, making future profitability a key focus for investors.…more
$17.82+3.97%vs prev close - 8.3Pre-market26.08.03 21:00
●●●●●●●● ●●●●● ●●●●●●
펠토스 테라퓨틱스가 오는 8월 13일 오전 8시 30분(미 동부시간)에 2026년 2분기 실적을 발표하고 컨퍼런스 콜을 진행합니다. 투자자들은 이번 실적 발표를 통해 회사의 주요 제품군인 ZELSUVMI 등의 매출 현황과 경영 성과를 확인할 수 있습니다.…more
$17.82+3.97%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report